DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
ARN-509 is an investigational drug.
There have been 38 clinical trials for ARN-509. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2020.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Adenocarcinoma, and Carcinoma. The leading clinical trial sponsors are Janssen Scientific Affairs, LLC, Aragon Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are forty US patents protecting this investigational drug and five hundred and two international patents.
Recent Clinical Trials for ARN-509
|Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer||National Cancer Institute (NCI)||Phase 2|
|Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer||Oregon Health and Science University||Phase 2|
|Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer||OHSU Knight Cancer Institute||Phase 2|
Top disease conditions for ARN-509
Top clinical trial sponsors for ARN-509
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ARN-509||Start Trial||Substituted thiohydantoin derivatives as androgen receptor antagonists||Janssen Pharmaceutica NV (Beerse, BE)||Start Trial|
|ARN-509||Start Trial||Androgen receptor modulators and uses thereof||Aragon Pharmaceuticals, Inc. (San Diego, CA)||Start Trial|
|ARN-509||Start Trial||Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer||Aragon Pharmaceuticals, Inc. (San Diego, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|